Target: ATG7
Conjugate: ATTO 594
Product Type: Polyclonal
Immunogen: Synthetic peptide from the N-terminal of Human ATG7
Swiss-Prot: O95352
Purification: Peptide Affinity Purified
Storage Buffer: 640.91mM DMSO, 136.36mM Ethanolamine, and 9.09mM Sodium Bicarbonate in 90.9% PBS
Concentration: 1 mg/ml
Specificity: Detects 77.9 kDa.
Cellular Localization: Cytoplasm / Preautophagosomal Structure
Tissue Specificity: Widely expressed, especially in kidney, liver, lymph nodes and bone marrow.
Scientific Background: ATG7 in conjuction with ATG10, mediates the formation of the autophagosome when ATG12 is covalently bound to ATG5 and targets to autophagosome vesicles. It also activates ATG8, and is crucial for amino acid supply in neonates.
References: 1. Mizushima N., et al. (1998) J Biol Chem. 273: 33889-92.2. Mizushima N., et al. (1998) Nature. 395: 395-8.3. Suzuki K., et al. (2001) EMBO J. 20: 5971-81.4. Tanida I., et al. (1999) Mol Biol Cell. 10: 1367-79.5. Shintani T., et al. (1999) EMBO J. 18: 5234-41.
Field of Use: Not for use in humans. Not for use in diagnostics or therapeutics. For in vitro research use only.
Deutsch
English
